Rosuvastatin and weight changes
Pro Research Analysisby 
Searched over 200M research papers
Rosuvastatin and Weight Changes: Effects in Animal and Human Studies
Rosuvastatin and Body Weight in Animal Models of Obesity
Several studies have examined the impact of rosuvastatin on body weight, particularly in the context of high-fat or high-fructose diets that induce obesity in animal models. In mice and rats fed high-fat diets, rosuvastatin was primarily effective in improving metabolic parameters such as lipid profiles, insulin sensitivity, and glucose tolerance, but its effect on body weight was less pronounced or inconsistent. For example, in a mouse study, rosuvastatin improved glucometabolic profiles and pancreatic β-cell function in a dose-dependent manner, but the main focus was on metabolic improvements rather than direct weight reduction . Similarly, in rats exposed to a high-fructose diet, rosuvastatin reduced lipid levels and inflammation but did not specifically report significant weight loss as a primary outcome .
In another rat study involving oral contraceptives and a high-fat diet, rosuvastatin helped prevent increases in triglycerides and total cholesterol, but only fenofibrate, not rosuvastatin, significantly prevented weight gain . This suggests that while rosuvastatin can improve metabolic health, its direct effect on weight gain or loss may be limited in these animal models.
Rosuvastatin and Weight Changes in Human Studies
In clinical settings, the effect of rosuvastatin on body weight appears minimal. A study in heart transplant patients who switched to rosuvastatin from other statins found no significant difference in body weight after the switch, despite improvements in lipid profiles and a higher rate of achieving LDL cholesterol targets . This aligns with findings from animal studies, indicating that rosuvastatin’s primary benefits are metabolic rather than related to weight loss.
Mechanisms and Pharmacokinetics in Obesity
Obesity can alter the pharmacokinetics of rosuvastatin. In rats with high-fat diet-induced obesity, decreased hepatic uptake of rosuvastatin was observed, leading to higher blood concentrations of the drug. This was attributed to inhibition of the hepatic Pxr-Oatp2 pathway, suggesting that dose adjustments may be necessary in obese patients to avoid potential side effects . However, neither weight loss nor gastric bypass surgery in humans significantly affected rosuvastatin’s pharmacokinetics to a clinically relevant degree, indicating that moderate weight changes do not necessitate major dosing changes .
Combination Therapies and Weight Effects
Some studies have explored combination therapies involving rosuvastatin. For example, combining rosuvastatin with atenolol in bilayer tablets for rabbits with diet-induced obesity resulted in improved lipid profiles, reduced weight gain, and normalized blood pressure compared to controls . Additionally, combining rosuvastatin with the capsaicinoid nonivamide in rats showed a synergistic effect, improving insulin sensitivity and vascular function, and reducing blood pressure and oxidative stress, though the primary focus was on metabolic and vascular outcomes rather than weight loss .
Temporary Weight Changes and Side Effects
In a study where male mice were exposed to rosuvastatin from pre-puberty to adulthood, a temporary reduction in body mass gain was observed, along with reduced food and water consumption. However, these effects were transient, and the main findings related to hepatic adaptation rather than sustained weight loss .
Conclusion
Overall, rosuvastatin is effective in improving metabolic health, particularly lipid profiles and insulin sensitivity, in both animal models and humans with obesity or metabolic syndrome. However, its direct effect on body weight is minimal or inconsistent, with most studies showing little to no significant weight loss attributable to rosuvastatin alone. Combination therapies may offer additional benefits, but for weight management, other interventions or medications may be more effective. Rosuvastatin’s primary value remains in cardiovascular risk reduction and metabolic improvement rather than weight control Al-Kuraishy2019Putri2022Hovd2023+6 MORE.
Sources and full results
Most relevant research papers on this topic